glp 1 drug class A schematic overview of GLP-1 receptor agonists: classification, GLP-1-based therapies for diabetes, obesity

Obesity is an alarmingly common chronic weight gain disorder characterized by excessive fat deposition that often increases the risk of type 2 diabetes (T2D) and cardiovascular diseases (CVD)

Diabetes Care 2023;47(Suppl 1):S1S322

They showed that 6 months of GLP-1-RA therapy provided 8.8% total weight loss and 2.9 kg/m 2 BMI loss

Ongoing research continues to evaluate the role of these agents in populations without diabetes, particularly in the context of obesity and primary cardiovascular prevention, suggesting that their therapeutic reach may expand further in the coming years

(2005) Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity (2020)